178 related articles for article (PubMed ID: 19490960)
1. Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation.
Pannaraj PS; Edwards MS; Ewing KT; Lewis AL; Rench MA; Baker CJ
Vaccine; 2009 Jul; 27(33):4452-6. PubMed ID: 19490960
[TBL] [Abstract][Full Text] [Related]
2. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
[TBL] [Abstract][Full Text] [Related]
3. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines.
Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Edwards MS; Kasper DL
J Infect Dis; 2004 Mar; 189(6):1103-12. PubMed ID: 14999615
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
[TBL] [Abstract][Full Text] [Related]
5. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines.
Yang HH; Madoff LC; Guttormsen HK; Liu YD; Paoletti LC
Infect Immun; 2007 Jul; 75(7):3455-61. PubMed ID: 17470542
[TBL] [Abstract][Full Text] [Related]
6. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.
Yang HH; Mascuch SJ; Madoff LC; Paoletti LC
Clin Vaccine Immunol; 2008 Jul; 15(7):1035-41. PubMed ID: 18463225
[TBL] [Abstract][Full Text] [Related]
7. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS
J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173
[TBL] [Abstract][Full Text] [Related]
9. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
Paoletti LC; Rench MA; Kasper DL; Molrine D; Ambrosino D; Baker CJ
Infect Immun; 2001 Nov; 69(11):6696-701. PubMed ID: 11598040
[TBL] [Abstract][Full Text] [Related]
10. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old.
Palazzi DL; Rench MA; Edwards MS; Baker CJ
J Infect Dis; 2004 Aug; 190(3):558-64. PubMed ID: 15243932
[TBL] [Abstract][Full Text] [Related]
11. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
12. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults.
Baker CJ; Rench MA; Paoletti LC; Edwards MS
Vaccine; 2007 Jan; 25(1):55-63. PubMed ID: 16919857
[TBL] [Abstract][Full Text] [Related]
13. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.
Baker CJ; Paoletti LC; Rench MA; Guttormsen HK; Carey VJ; Hickman ME; Kasper DL
J Infect Dis; 2000 Oct; 182(4):1129-38. PubMed ID: 10979909
[TBL] [Abstract][Full Text] [Related]
14. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
[TBL] [Abstract][Full Text] [Related]
15. Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.
Goyette-Desjardins G; Calzas C; Shiao TC; Neubauer A; Kempker J; Roy R; Gottschalk M; Segura M
Infect Immun; 2016 Jul; 84(7):2059-2075. PubMed ID: 27113360
[TBL] [Abstract][Full Text] [Related]
16. Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.
Edwards MS; Lane HJ; Hillier SL; Rench MA; Baker CJ
Vaccine; 2012 Jun; 30(28):4123-6. PubMed ID: 22537994
[TBL] [Abstract][Full Text] [Related]
17. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines.
Fattom AI; Sarwar J; Basham L; Ennifar S; Naso R
Infect Immun; 1998 Oct; 66(10):4588-92. PubMed ID: 9746554
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
Baker CJ; Paoletti LC; Wessels MR; Guttormsen HK; Rench MA; Hickman ME; Kasper DL
J Infect Dis; 1999 Jan; 179(1):142-50. PubMed ID: 9841833
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice.
Paoletti LC; Pinel J; Rodewald AK; Kasper DL
J Infect Dis; 1997 May; 175(5):1237-9. PubMed ID: 9129094
[TBL] [Abstract][Full Text] [Related]
20. Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention.
Palmeiro JK; De Carvalho NS; Botelho AC; Fracalanzza SE; Madeira HM; Dalla-Costa LM
Vaccine; 2011 May; 29(21):3729-30. PubMed ID: 21414381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
